MTA1: A Vital Modulator in Prostate Cancer

Author:

Qian Haili1,Zhang Yong23,Ma Jialu2ORCID,Li Chunxiao1

Affiliation:

1. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2. Graduate School of Hebei Medical University, Shijiazhuang, China

3. Department of Urology Surgery, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Abstract

Abstract: Prostate cancer (PCa) is the most frequent cancer of the male genitourinary system and the second most common cancer in men worldwide. PCa has become one of the leading diseases endangering men's health in Asia in recent years, with a large increase in morbidity and mortality. MTA1 (metastasis-associated antigen-1), a transcriptional coregulator involved in histone deacetylation and nucleosome remodeling, is a member of the MTA family. MTA1 is involved in cell signaling, chromosomal remodeling, and transcriptional activities, all of which are important for epithelial cell progression, invasion, and growth. MTA1 has been demonstrated to play a significant role in the formation, progression, and metastasis of PCa, and MTA1 expression is specifically linked to PCa bone metastases. Therefore, MTA1 may be a potential target for PCa prevention and treatment. Here, we reviewed the structure, function, and expression of MTA1 in PCa as well as drugs that target MTA1 to highlight a potential new treatment for PCa.

Funder

National Natural Science Foundation of China

National Key Research and Development Program of China

Publisher

Bentham Science Publishers Ltd.

Subject

Cell Biology,Molecular Biology,Biochemistry,General Medicine

Reference79 articles.

1. Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global Cancer Statistics 2020: GLOBOCAN esti-mates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249

2. Culp M.B.; Soerjomataram I.; Efstathiou J.A.; Bray F.; Jemal A.; Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020,77(1),38-52

3. Bekelman J.E.; Rumble R.B.; Chen R.C.; Pisansky T.M.; Finelli A.; Feifer A.; Nguyen P.L.; Loblaw D.A.; Tagawa S.T.; Gillessen S.; Morgan T.M.; Liu G.; Vapiwala N.; Haluschak J.J.; Stephenson A.; Touijer K.; Kungel T.; Freedland S.J.; Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an american urological association/american society for radiation oncolo-gy/society of urologic oncology guideline. J Clin Oncol 2018,36(32),3251-3258

4. Rice M.A.; Malhotra S.V.; Stoyanova T.; Second-generation antiandrogens: From discovery to standard of care in castration resistant prostate cancer. Front Oncol 2019,9,801

5. Ryan C.J.; Smith M.R.; Fizazi K.; Saad F.; Mulders P.F.; Sternberg C.N.; Miller K.; Logothetis C.J.; Shore N.D.; Small E.J.; Carles J.; Flaig T.W.; Taplin M.E.; Higano C.S.; de Souza P.; de Bono J.S.; Griffin T.W.; De Porre P.; Yu M.K.; Park Y.C.; Li J.; Kheoh T.; Naini V.; Molina A.; Rathkopf D.E.; Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015,16(2),152-160

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3